Rating Change
Baird analysts reiterated a Outperform rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on June 30, 2026.
reiterateNASDAQ:TSHA
Baird Reiterates Outperform Rating on Taysha Gene Therapies, Inc. (TSHA)
Rating Change Baird analysts reiterated a Outperform rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on June 30, 2026. Market Context Taysha Gene Therapies, Inc.
Market Context
Taysha Gene Therapies, Inc. operates in the Healthcare sector. The stock currently trades at $7.06 with a market capitalization of $1.5B.
Analyst coverage from Baird provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Taysha Gene Therapies, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Taysha Gene Therapies, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 30, 2026 | Baird | Outperform | N/A |
| Jun 23, 2026 | BMO Capital | Outperform | N/A |
| Jun 23, 2026 | B of A Securities | Buy | N/A |
| Jun 23, 2026 | Citizens | Market Outperform | N/A |
| Jun 22, 2026 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TSHA Stock Page
Frequently Asked Questions
What does a Outperform rating mean for TSHA?
A Outperform rating from Baird reflects the analyst's outlook on Taysha Gene Therapies, Inc. (NASDAQ:TSHA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TSHA forecast page.